Daniel Bryce Landi
Assistant Professor of Pediatrics
Current Appointments & Affiliations
- Assistant Professor of Pediatrics, Pediatrics, Hematology-Oncology, Pediatrics 2021
Contact Information
- 330 Trent Drive, Room 390, Durham, NC 27710
- Box 102382, Durham, NC 27710
-
daniel.landi@duke.edu
(919) 668-6288
- Background
-
Education, Training, & Certifications
- Hemoatology/Oncology Fellowship, Pediatrics, Baylor College of Medicine 2013 - 2016
- Pediatric Internship and Residency, Pediatrics, Duke University School of Medicine 2009 - 2012
- M.D., University of Colorado School of Medicine 2009
-
Previous Appointments & Affiliations
- Assistant Professor of Pediatrics, Pediatrics, Hematology-Oncology, Pediatrics 2017 - 2020
- Medical Instructor in the Department of Pediatrics, Pediatrics, Transplant and Cellular Therapy, Pediatrics 2012 - 2013
- Research
-
Selected Grants
- A Phase 1/2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Relapsed/Refractory Solid Tumors Harboring a Mutation in KIT or PDGFRA awarded by Blueprint Medicines Corporation 2022 - 2027
- PNOC 019: A Randomized, Double-Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG) awarded by The Regents of the University of California 2021 - 2026
- DAY 101-001, A Phase 2 Study of the Oral pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Mutated Low Grade Glioma awarded by DOT Therapeutics-1 2021 - 2026
- Phase 2 PVSRIPO and the Checkpoint Inhibitor Pembrolizumab in Recurrent Glioblastoma awarded by Istari Oncology 2021 - 2025
- Phase 2 trial of a novel peptide vaccine targeting CMV antigen for newly diagnosed pediatric high grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastoma awarded by National Institutes of Health 2021 - 2025
- PNOC022 A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial D awarded by The Regents of the University of California 2022 - 2023
- Dose-finding and Safety Study of PVSRIPO Against Recurrent WHO Grade IV Malignant Glioma awarded by Istari Oncology 2020 - 2022
- Qualitative Interviews with Recurrent Glioblastoma Patients and their Caregivers awarded by Istari Oncology 2021 - 2022
- PBTC-029 awarded by St. Jude Children's Research Hospital 2017 - 2022
- A Randomized, Multicenter, Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) Alone or in Combination with Lomustine in Recurrent WHO Grade IV Malignant Glioma Patients awarded by Istari Oncology 2018 - 2021
-
External Relationships
- Roche
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Thompson, Eric M., David Ashley, and Daniel Landi. “Current medulloblastoma subgroup specific clinical trials.” Transl Pediatr 9, no. 2 (April 2020): 157–62. https://doi.org/10.21037/tp.2020.03.03.Full Text Link to Item
-
Thompson, Eric M., Daniel Landi, David Ashley, Stephen T. Keir, and Darell Bigner. “Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.” J Neurooncol 140, no. 2 (November 2018): 261–68. https://doi.org/10.1007/s11060-018-2975-5.Full Text Link to Item
-
Tan, Char-Loo, Daniel Landi, Herbert Fuchs, and Roger E. McLendon. “Novel case of recurrent intraventricular atypical central neurocytoma with prominent gangliogliomatous differentiation in a 10-year-old boy with 10 years of follow up.” Neuropathology 38, no. 5 (October 2018): 542–48. https://doi.org/10.1111/neup.12502.Full Text Link to Item
-
Landi, Daniel B., Eric M. Thompson, and David M. Ashley. “Immunotherapy for pediatric brain tumors.” Neuroimmunology and Neuroinflammation 5, no. 7 (July 23, 2018): 29–29. https://doi.org/10.20517/2347-8659.2018.35.Full Text
-
Ahmed, Nabil, Vita Brawley, Meenakshi Hegde, Kevin Bielamowicz, Mamta Kalra, Daniel Landi, Catherine Robertson, et al. “HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma.” Jama Oncology 3, no. 8 (August 1, 2017): 1094–1094. https://doi.org/10.1001/jamaoncol.2017.0184.Full Text
-
Hegde, Meenakshi, Malini Mukherjee, Zakaria Grada, Antonella Pignata, Daniel Landi, Shoba A. Navai, Amanda Wakefield, et al. “Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.” Journal of Clinical Investigation 126, no. 8 (July 18, 2016): 3036–52. https://doi.org/10.1172/jci83416.Full Text
-
Wakefield, Amanda, Antonella Pignata, Alexia Ghazi, Aidin Ashoori, Meenakshi Hegde, Daniel Landi, Tara Gray, et al. “Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients.” Journal of Neuro Oncology 125, no. 2 (November 2015): 307–15. https://doi.org/10.1007/s11060-015-1905-z.Full Text
-
Shah, Nirmish, Margo Rollins, Daniel Landi, Radhika Shah, Jonathan Bae, and Laura M. De Castro. “Differences in pain management between hematologists and hospitalists caring for patients with sickle cell disease hospitalized for vasoocclusive crisis.” Clin J Pain 30, no. 3 (March 2014): 266–68. https://doi.org/10.1097/AJP.0b013e318295ec04.Full Text Link to Item
-
Boelens, Jaap Jan, Mieke Aldenhoven, Duncan Purtill, Annalisa Ruggeri, Todd Defor, Robert Wynn, Ed Wraith, et al. “Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning.” Blood 121, no. 19 (May 9, 2013): 3981–87. https://doi.org/10.1182/blood-2012-09-455238.Full Text Open Access Copy Link to Item
-
Landi, Daniel, Michele G. Beckman, Nirmish R. Shah, Paula Bockenstedt, Althea M. Grant, John A. Heit, Nigel S. Key, et al. “Characteristics of abdominal vein thrombosis in children and adults.” Thromb Haemost 109, no. 4 (April 2013): 625–32. https://doi.org/10.1160/TH12-08-0568.Full Text Open Access Copy Link to Item
-
Landi, Daniel, Evelyn Lockhart, Sara E. Miller, Michael Datto, Catherine Rehder, Angela Kanaly, and Courtney D. Thornburg. “Report of a young girl with MYH9 mutation and review of the literature.” J Pediatr Hematol Oncol 34, no. 7 (October 2012): 538–40. https://doi.org/10.1097/MPH.0b013e3182678fc9.Full Text Open Access Copy Link to Item
-
Shah, Nirmish, Daniel Landi, Radhika Shah, Jennifer Rothman, Laura M. De Castro, and Courtney D. Thornburg. “Complications of implantable venous access devices in patients with sickle cell disease.” Am J Hematol 87, no. 2 (February 2012): 224–26. https://doi.org/10.1002/ajh.22230.Full Text Open Access Copy Link to Item
-
Shah, Nirmish R., Daniel B. Landi, Susan G. Kreissman, Evan Kulbachi, and Cassandra Moran. “Presentation and outcomes for children with bone marrow necrosis and acute lymphoblastic leukemia: a literature review.” J Pediatr Hematol Oncol 33, no. 7 (October 2011): e316–19. https://doi.org/10.1097/MPH.0b013e318223fe9b.Full Text Open Access Copy Link to Item
-
-
Conference Papers
-
Batich, Kristen, Duane Mitchell, Patrick Healy, James Herndon, Gloria Broadwater, Gunn Michael, Min-Nung Huang, et al. “CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA.” In Neuro Oncology, 23:vi51–vi51. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.202.Full Text Open Access Copy Link to Item
-
Desjardins, Annick, Matthias Gromeier, Henry Friedman, Daniel Landi, Allan Friedman, David M. Ashley, William Curry, et al. “IMMU-26. SAFETY AND EFFICACY OF PVSRIPO IN RECURRENT GLIOBLASTOMA: LONG-TERM FOLLOW-UP AND INITIAL MULTICENTER RESULTS.” In Neuro Oncology, 23:vi97–vi97. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.385.Full Text
-
Johnson, Margaret, Mustafa Khasraw, Jung-Young Kim, Nicole Cort, James Herndon, Luis Ramirez, Eric Lipp, et al. “QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE.” In Neuro Oncology, 23:vi189–vi189. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.748.Full Text Open Access Copy Link to Item
-
Peters, Katherine, Mallika Patel, Candice Alford, Gerardo Chavez, Jung-Young Kim, Jennifer Durling, Tracy Novack, et al. “INNV-20. RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB.” In Neuro Oncology, 23:vi109–vi109. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.431.Full Text Open Access Copy Link to Item
-
Peters, Katherine, Mary Affronti, Jung-Young Kim, Mallika Patel, Margaret Johnson, David Bartlett, Nicole Cort, et al. “QOLP-10. A LONGITUDINAL OBSERVATIONAL STUDY OF EXERCISE BEHAVIOR IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR-TREATING FIELDS.” In Neuro Oncology, 23:vi184–85. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.731.Full Text Open Access Copy Link to Item
-
Petitt, Zoey, James Herndon, Oren Gottfried, Christina Cone, Daniel Landi, Mustafa Khasraw, Henry Friedman, et al. “INNV-31. NEURO-ONCOLOGY OUTPATIENT SATISFACTION IS MAINTAINED IN THE ERA OF COVID-19 TELEMEDICINE.” In Neuro Oncology, 23:vi112–vi112. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.442.Full Text Open Access Copy
-
Sloan, Andrew, Robin Buerki, Daniel Landi, Annick Desjardins, Allan Friedman, Prakash Ambady, Kevin Becker, et al. “CTIM-18. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA.” In Neuro Oncology, 23:vi53–54. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.210.Full Text
-
Wilkinson, Daniel, Katherine Ryan, Vidyalakshmi Chandramohan, Daniel Landi, Darell Bigner, and Peter Fecci. “EXTH-59. GENERATION OF A THIRD GENERATION CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOBLASTOMA.” In Neuro Oncology, 23:vi176–vi176. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.698.Full Text
-
Hanzlik, Emily, Bridget Archambault, Mays Dairi, Kristin Schroeder, Mallika Patel, Eric S. Lipp, Song Boucree, Katherine Peters, David Ashley, and Daniel Landi. “LGG-08. TREATMENT OUTCOMES AND TOLERABILITY OF TRAMETINIB IN PROGRESSIVE CIRCUMSCRIBED LOW-GRADE GLIOMAS.” In Neuro Oncology, 23:i32–33. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab090.132.Full Text
-
Thompson, Eric, Daniel Landi, Gerald Archer, Eric Lipp, Ashley Walter, Bridget Archambault, Bea Balajonda, et al. “EPCT-01. A NOVEL PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL.” In Neuro Oncology, 23:i46–i46. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab090.187.Full Text Link to Item
-
Kilburn, Lindsay Baker, Nada Jabado, Andrea Franson, Susan N. Chi, Michael J. Fisher, Darren R. Hargrave, Jordan R. Hansford, et al. “FIREFLY-1: A phase 2 study of the pan-RAF inhibitor DAY101 in pediatric patients with low-grade glioma.” In Journal of Clinical Oncology, 39:TPS10056–TPS10056. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.tps10056.Full Text
-
Sloan, Andrew E., Robin Arthur Buerki, Christopher Murphy, Andrea True Kelly, Prakash Ambady, Michael Brown, Nicholas A. Butowski, et al. “LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.” In Journal of Clinical Oncology, 39:TPS2065–TPS2065. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.tps2065.Full Text
-
Cohen, Kenneth, Susan Chi, Cynthia Hawkins, Fausto Rodriguez, Wendy London, Robert Craig Castellino, Dolly Aguilera, et al. “MBCL-25. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA: UPDATED OUTCOMES.” In Neuro Oncology, 22:iii393–94. Oxford University Press (OUP), 2020. https://doi.org/10.1093/neuonc/noaa222.501.Full Text
-
Landi, Daniel, Gary Archer, Timothy Driscoll, Eric Lipp, Bridget Archambault, Eric Thompson, Charlene Flahiff, et al. “EPCT-13. CMV PP65 RNA-PULSED DENDRITIC CELL VACCINES FOR PEDIATRIC GLIOBLASTOMA AND MEDULLOBLASTOMA: PHASE I TRIAL RESULTS.” In Neuro Oncology, 22:iii306–iii306. Oxford University Press (OUP), 2020. https://doi.org/10.1093/neuonc/noaa222.136.Full Text
-
Mosaheb, Mubeen, Daniel Landi, Elena Dobrikova, Michael Brown, Yuanfan Yang, Jana Cable, Hideho Okada, et al. “THER-05. GENETICALLY STABLE POLIOVIRUS VECTOR CARRYING H3.3K27M ANTIGEN FOR TREATMENT OF DIFFUSE MIDLINE GLIOMA BY INTRAMUSCULAR INJECTION.” In Neuro Oncology, 22:iii472–iii472. Oxford University Press (OUP), 2020. https://doi.org/10.1093/neuonc/noaa222.855.Full Text
-
Noyd, David, Claire Howell, Kevin Oeffinger, Daniel Landi, and Kristin Schroeder. “EPID-16. INTEGRATION OF EHR AND CANCER REGISTRY DATA TO CONSTRUCT A PEDIATRIC NEURO-ONCOLOGY SURVIVORSHIP COHORT AND IMPROVE LONG-TERM FOLLOW-UP CARE.” In Neuro Oncology, 22:iii322–iii322. Oxford University Press (OUP), 2020. https://doi.org/10.1093/neuonc/noaa222.202.Full Text
-
Desjardins, Annick, Dina Randazzo, Vidya Chandramohan, Katherine Peters, Margaret Johnson, Daniel Landi, Mustafa Khasraw, et al. “CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG).” In Neuro Oncology, 22:ii38–ii38. Oxford University Press (OUP), 2020. https://doi.org/10.1093/neuonc/noaa215.157.Full Text
-
Randazzo, Dina, Evan Buckley, James Herndon, Nicole Cort, Mary Affronti, Eric Lipp, Annick Desjardins, et al. “QOLP-20. A FEASIBILITY STUDY UTILIZING MINDFULNESS MEDITATION DURING CONCOMITANT CHEMORADIATION IN MALIGNANT GLIOMA PATIENTS: HEALTH-REPORTED QUALITY OF LIFE (HRQOL) RESULTS.” In Neuro Oncology, 22:ii179–ii179. Oxford University Press (OUP), 2020. https://doi.org/10.1093/neuonc/noaa215.745.Full Text
-
Ryan, Katherine, Daniel Wilkinson, Daniel Landi, and Peter Fecci. “DDRE-20. GENERATION OF A HIGH-AFFINITY EGFR/EGFRvIII-TARGETED D2C7 CAR-T CELL.” In Neuro Oncology, 22:ii65–66. Oxford University Press (OUP), 2020. https://doi.org/10.1093/neuonc/noaa215.265.Full Text
-
Thompson, Eric, Daniel Landi, Eric Lipp, Bea Balajonda, James Herndon, Evan Buckley, Charlene Flahiff, et al. “CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL.” In Neuro Oncology, 22:ii37–ii37. Oxford University Press (OUP), 2020. https://doi.org/10.1093/neuonc/noaa215.155.Full Text Open Access Copy Link to Item
-
Walsh, Kyle, Joanne Xiu, Giselle López, Daniel Landi, Zachary Reitman, Sandeep Mittal, Andrew Brenner, et al. “BIOM-17. BRAF MUTATION IS AN EARLY EVENT IN THE EVOLUTION OF A SUBSET OF GLIOBLASTOMAS AND IS ASSOCIATED WITH INCREASED PD-L1 EXPRESSION.” In Neuro Oncology, 22:ii5–ii5. Oxford University Press (OUP), 2020. https://doi.org/10.1093/neuonc/noaa215.017.Full Text
-
Archambault, Bridget, Daniel Landi, and Kristin Schroeder. “QOLP-34. DOSE FREQUENCY MODIFICATION OF TRAMETINIB TO MITIGATE SEVERE RASH AND IMPROVE QUALITY OF LIFE IN PEDIATRIC LOW-GRADE GLIOMA PATIENTS.” In Neuro Oncology, 21:vi205–vi205. Oxford University Press (OUP), 2019. https://doi.org/10.1093/neuonc/noz175.854.Full Text
-
Landi, Daniel, Gary Archer, Timothy Driscoll, James Herndon, John Sampson, and David Ashley. “PDCT-10. FEASIBILITY OF LEUKAPHERESIS FOR HARVESTING MONOCYTES AND GENERATING AUTOLOGOUS DENDRITIC CELL VACCINES IN CHILDREN WITH MALIGNANT BRAIN TUMORS.” In Neuro Oncology, 21:vi185–vi185. Oxford University Press (OUP), 2019. https://doi.org/10.1093/neuonc/noz175.772.Full Text
-
Randazzo, Dina, Jenny Jackman, James Herndon, Mary Affronti, Eric Lipp, Nicole Cort, Annick Desjardins, et al. “QOLP-29. MINDFULNESS MEDITATION PRACTICE IN MALIGNANT GLIOMA PATIENTS THROUGHOUT CONCOMITANT RADIATION AND TEMOZOLOMIDE: A FEASIBILITY STUDY.” In Neuro Oncology, 21:vi204–vi204. Oxford University Press (OUP), 2019. https://doi.org/10.1093/neuonc/noz175.849.Full Text Link to Item
-
Thompson, Eric, Daniel Landi, David Ashley, Steve Keir, and Darell Bigner. “EXTH-79. BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS.” In Neuro Oncology, 20:vi102–vi102. Oxford University Press (OUP), 2018. https://doi.org/10.1093/neuonc/noy148.426.Full Text
-
Ashley, David M., Eric M. Thompson, Daniel Landi, Annick Desjardins, Allan H. Friedman, Stevie Threatt, James E. Herndon, II, et al. “HGG-22. PHASE 1b STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN.” In Neuro Oncology, 20:i93–i93. Oxford University Press (OUP), 2018. https://doi.org/10.1093/neuonc/noy059.294.Full Text
-
Landi, Daniel, Eric Thompson, James Herndon, John Sampson, and David Ashley. “IMMU-23. CMV pp65 RNA-PULSED DENDRITIC CELL VACCINES FOR PEDIATRIC GLIOBLASTOMA AND MEDULLOBLASTOMA: A PHASE I TRIAL.” In Neuro Oncology, 20:i103–i103. Oxford University Press (OUP), 2018. https://doi.org/10.1093/neuonc/noy059.339.Full Text
-
Landi, Daniel, Eric Thompson, Roger McLendon, Annick Desjardins, Vidya Chandramohan, David Ashley, and Darell Bigner. “IMMU-21. TARGETING EGFR IN HYPOMUTATED PEDIATRIC BRAIN TUMORS USING THE D2C7 IMMUNOTOXIN.” In Neuro Oncology, 20:i103–i103. Oxford University Press (OUP), 2018. https://doi.org/10.1093/neuonc/noy059.337.Full Text
-
Landi, D. B., J. T. Rahkola, and E. N. Janoff. “MEASURING ANTIBODY-SECRETING B-CELL RESPONSES TO IMMUNOLOGICAL STIMULI.” In Journal of Investigative Medicine, 55:S121–S121. SAGE Publications, 2007. https://doi.org/10.1097/00042871-200701010-00279.Full Text
-
Liu, C. C., M. F. Diaz-Aguado, D. B. Landi, and T. J. Moon. “Micromechanics applied to cytoskeleton dynamics: Actin substructure modeling.” In Biophysical Journal, 86:301A-302A. BIOPHYSICAL SOCIETY, 2004.Link to Item
-
Frost, Erin I., Andrew Bellantoni, and Daniel Landi. “A Sheep in Wolf’s Clothing: An Atypical Etiology of a Cerebellar Lesion. (Accepted),” n.d.
-
Frost, Erin I., Andrew Bellantoni, and Daniel Landi. “A Sheep in Wolf’s Clothing: An Atypical Etiology of a Cerebellar Lesion. (Accepted),” n.d.
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.